Abstract
Many randomized clinical controlled trials have confirmed the efficacy and safety of calcium dobesilate in treating diabetic retinopathy (DR). This systematic review critically evaluated the evidence that links calcium dobesilate to DR. In this fixed-effects meta-analysis, a total of 221 pertinent English-language articles published between January 1975 and October 2013 were identified. Systematic searches of PUBMED, Springer Link and the Cochrane Clinical Trials Database were conducted using the keywords “diabetic retinopathy” and “calcium dobesilate”. The extracted information included the study design, inclusion and exclusion criteria, setting, sample size, participant mean age, treatment regime, mean change in best corrected visual acuity, laboratory parameters, capillary fragility, intraocular pressure and fundus manifestations based on the findings of fluorescent angiography. The summary statistics indicated that calcium dobesilate was significantly associated with improving retinal microaneurysms (RR: 0.62, 95%CI: 0.42–0.90, P=0.01), retinalhemorrhages (RR: 0.39, 95% CI: 0.17–0.88, P=0.02); exudates (RR: 0.31, 95% CI: 0.12–0.81, P=0.02), reduction of whole blood viscosity (MD: −0.57 CP, 95% CI: −0.75 to −0.38, P<0.001), plasma viscosity (MD: −0.36 CP, 95% CI: −0.63 to −0.09, P=0.01) and blood cholesterol (MD: −0.48 mg mL−1, 95% CI: −0.64−0.33, P<0.00001). Intraocular pressure was also significantly reduced (MD: −5.59 mmHg, 95% CI: −6.69 to −4.50, P<0.00001). The results indicate that calcium dobesilate effectively treats DR at the systematic and local ocular levels.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Blindness caused by diabetes—Massachusetts, 1987–1994. MMWR Morb Mortal Wkly Rep, 1996, 45: 937–941
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O’Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta- Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012, 35: 556–564
Xie X, Xu L, Yang H, Wang S, Jonas JB. Frequency of diabetic retinopathy in the adult population in China: the Beijing Eye Study 2001. Int Ophthalmol, 2009, 29: 485–493
Xu J, Wei WB, Yuan MX, Yuan SY, Wan G, Zheng YY, Li YB, Wang S, Xu L, Fu HJ, Zhu LX, Pu XL, Zhang JD, Du XP, Li YL, Ji Y, Gu XN, Li Y, Pan SF, Cui XL, Bai W, Chen YJ, Wang ZM, Zhu QS, Gao Y, Liu de Y, Ji YT, Yang Z, Jonas JB. Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina, 2012, 32: 322–329
Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, Sun LP, Friedman DS, Wang NL, Wong TY. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology, 2009, 116: 461–467
ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010, 363: 233–244
Vekasi J, Koltai K, Gaal V, Toth A, Juricskay I, Kesmarky G. The effect of aspirin on hemorheological parameters of patients with diabetic retinopathy. Clin Hemorheol Microcirc, 2008, 39: 385–389
Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina, 2011, 31: 2084–2094
Wilkinson-Berka JL, Rana I, Armani R, Agrotis A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond), 2013, 124: 597–615
Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study. J Hypertens, 2011, 29: 1457–1462
Ribeiro ML, Caillon P, Gamba G, Cunha-Vaz J, group DX-rs. Efficacy of calcium dobesilate (Doxium(R)) on the blood-retinal barrier permeability in early diabetic retinopathy: a double-blind study. Invest Ophthalmol Vis Sci, 2004, 45: 4153–B614
Akbulut B. Calcium dobesilate and oxerutin: effectiveness of combination therapy. Phlebology, 1258, 25: 66–71
Ruiz E, Lorente R, Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Br J Pharmacol, 1997, 121: 711–716
Graber R, Farine JC, Losa GA. Calcium Dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis. Apoptosis, 1998, 3: 41–49
Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, Berta A, Garay RP. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol, 2001, 428: 277–286
Opreanu M, Lydic TA, Reid GE, McSorley KM, Esselman WJ, Busik JV. Inhibition of cytokine signaling in human retinal endothelial cells through downregulation of sphingomyelinases by docosahexaenoic acid. Invest Ophthalmol Vis Sci, 1167, 51: 3253–3263
Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J, Cunha-Vaz J, Ambrosio AF. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes, 2010, 59: 2637–2645
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17: 1–12
Larsen HW, Sander E, Hoppe R. The value of calcium dobesilate in the treatment of diabetic retinopathy. A controlled clinical trial. Diabetologia, 1977, 13: 105–109
Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res, 1991, 23: 12–20
Leite EB, Mota MC, de Abreu JR, Cunha-Vaz JG. Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol, 1990, 14: 81–88
Benarroch IS, de Salama Benarroch AR, Nano H, Perez H, Bisceglia H. Calcium dobesilate as a treatment for capillary fragility in diabetic retinopathy. Ophthalmologica, 1977, 174: 47–51
Benarroch IS, Brodsky M, Rubinstein A, Viggiano C, Salama EA. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res, 1985, 17: 131–138
Vojnikovic B. Hyperviscosity in whole blood, plasma, and aqueous humor decreased by doxium (calcuim dobesilate) in diabetics with retinopathy and glaucoma: a double-blind controlled study. Ophthalmic Res, 1984, 16: 150–162
Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol, 2006, 244: 1591–1600
Javadzadeh A, Ghorbanihaghjo A, Adl FH, Andalib D, Khojasteh-Jafari H, Ghabili K. Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis, 2013, 19: 62–68
Sander B, Thornit DN, Colmorn L, Strom C, Girach A, Hubbard LD, Lund-Andersen H, Larsen M. Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. Invest Ophthalmol Vis Sci, 2007, 48: 3983–3987
Benarroch IS, de Salama Benarroch AR, Nano H, Perez H, Bisceglia H. Calcium dobesilate as a treatment for capillary fragility in diabetic retinopathy. Ophthalmologica, 1974, 168: 370–375
Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes, 2008, 57: 1026–1033
Leske MC, Wu SY, Hennis A, Hyman L, Nemesure B, Yang L, Schachat AP. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies. Ophthalmology, 2005, 112: 799–805
Varma R, Macias GL, Torres M, Klein R, Pena FY, Azen SP. Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. Ophthalmology, 2007, 114: 1332–1340
Benarous R, Sasongko MB, Qureshi S, Fenwick E, Dirani M, Wong TY, Lamoureux EL. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci, 1167, 52: 7464–7469
Agroiya P, Philip R, Saran S, Gutch M, Tyagi R, Gupta KK. Association of serum lipids with diabetic retinopathy in type 2 diabetes. Indian J Endocrinol Metab, 2013, 17: S335–337
Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost, 2000, 26: 529–537
Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet, 2002, 359: 515–519
Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ, 2007, 334: 349–351
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008, 336: 995–998
Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: review. BMJ, 2009, 338: b1732
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at link.springer.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Zhang, X., Liu, W., Wu, S. et al. Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis. Sci. China Life Sci. 58, 101–107 (2015). https://doi.org/10.1007/s11427-014-4792-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-014-4792-1